Compare Funko Inc (FNKO) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs McKesson Corporation — how do they compare? Funko Inc trades at $6.53 (market cap $363.97M), while McKesson Corporation trades at $937.98 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 298× Funko Inc's market cap, and McKesson Corporation pays a 0.4% dividend while Funko Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Funko Inc for 33 Days and McKesson Corporation for 74 Days on average.
| FNKO | MCK | |
|---|---|---|
Market Cap | $363.97M | $108.46B |
Volume | 1,422,651 | 712,607 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.10 | $995.69 |
52-Week Low | $2.81 | $725.17 |
Typical Hold Time | 33 Days | 74 Days |
Enterprise Value | $584.62M | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Funko (FNKO) trades at $6.31, up 3.27% with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with recent earnings beats and raised 2026 EBITDA guidance to $105M. Revenue declined to $908M in 2025 but shows stabilization with 2026 projections at $933M. Analyst consensus is mixed with 42.9% buy ratings and $7.58 price target, representing 20% upside potential.
Investment opportunity centers on turnaround execution with improving margins and debt reduction. Key risks include negative net income margins, competitive pressures in collectibles, and sensitivity to consumer discretionary spending. The stock offers value with low P/S of 0.38x but requires sustained profitability improvement to justify higher valuations.
McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.
The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
